Інформація призначена тільки для фахівців сфери охорони здоров'я, осіб,
які мають вищу або середню спеціальну медичну освіту.

Підтвердіть, що Ви є фахівцем у сфері охорони здоров'я.

Мобильная версия

Регистрация Забыли пароль?


Коморбідний ендокринологічний пацієнт
Коморбідний ендокринологічний пацієнт

Международный эндокринологический журнал Том 19, №6, 2023

Вернуться к номеру

Цукровий діабет і COVID-19: життя з подвійним ризиком

Цукровий діабет і COVID-19: життя з подвійним ризиком

Авторы: O.V. Muravlova, Z.O. Shaienko, I.L. Dvornyk, L.M. Sizova, V.I. Ilchenko, T.I. Purdenko, O.A. Shpetnyi
Poltava State Medical University, Poltava, Ukraine

Рубрики: Эндокринология

Разделы: Справочник специалиста

Версия для печати


Резюме

Мета: проаналізувати та узагальнити дослідження, проведені для визначення впливу COVID-19 на перебіг цукрового діабету та прояви хронічних ускладнень цього захворювання. Матеріали та методи. Ми здійснили пошук у базах даних PubMed і ScienceDirect, використовуючи наступний рядок: «SARS-CоV-2 або COVID-19 і діабет або гіперглікемія». Результати. Виявлено, що у хворих на цукровий діабет посилюється тяжкість перебігу COVID-19. ­Зокрема, зросла кількість тих, хто потребує інтенсивної терапії або штучної вентиляції легень. Така ж негативна динаміка спостерігається і за показником загальної смертності хворих на цукровий діабет. Було встановлено, що COVID-19 збільшує частоту розвитку діабету, включаючи діабетичний кетоацидоз, гіперосмолярний синдром, мозкового інсульту і розладів психічного здоров’я, що може потенціювати вплив COVID-19 на посилення проявів цукрового діабету і мати подвійний ризик для пацієнтів. Разом із цим спільність шляхів патогенезу цукрового діабету та COVID-19 зумовлює двонаправленість взаємодії при їх коморбідності. Аналіз досліджень показує, що гостра пандемія COVID-19 наклалася на пандемію уповільнених метаболічних захворювань, одним з яких є цукровий діабет. Як наслідок, у цих пацієнтів посилилася тяжкість перебігу COVID-19. Таким чином, цукровий діабет розглядається як фактор ризику тяжкості COVID-19. Висновки. Продемонстровано численні зв’язки між патогенетичними механізмами COVID-19 і цукровим діабетом. Незважаючи на це, у поточних дослідженнях показано лише скромні докази підвищеного ризику метаболічних, неврологічних і психіатричних ускладнень у пацієнтів із діабетом, які перенесли COVID-19. Однак поряд із прямим впливом інфікування пацієнтів змінюються і умови пандемії, що ускладнює доступ до необхідної допомоги та повинно враховуватися при вивченні клінічних наслідків COVID-19 у хворих на цукровий діабет.

Background. The purpose is to analyze and summarize the studies conducted to determine the impact of COVID-19 on the course of diabetes mellitus and the manifestations of chronic complications of this disease. Materials and methods. We did the search in PubMed and ScienceDirect databases using the following line: “SARS-CoV-2 or COVID-19 and diabetes or hyperglycemia”. Results. It was found that in patients with diabetes, the severity of COVID-19 is increased. In particular, the number of those who needed intensive care or artificial ventilation has elevated. The same negative trend is noted for the overall mortality rate in patients with diabetes. It has been found that COVID-19 contributes to an increase in the development of diabetes, including diabetic ketoacidosis, hyperosmolar syndrome, brain stroke and mental health disorders, which can potentiate the effect of COVID-19 in enhancing the manifestations of diabetes and double risk for these patients. Along with this, the common pathways of the pathogenesis of diabetes and COVID-19 determine the bidirectionality of the interaction in their comorbidity. Conclusions. We have demonstrated numerous links between COVID-19 pathogenetic mechanisms and diabetes. Despite this, current research shows only modest evidence of an increased risk of metabolic, neurological, and psychiatric complications in patients with diabetes who had COVID-19. However, along with the direct impact of patients’ infection, the conditions of pandemic are also affected, which complicate access to the necessary care and should be taken into account when studying the clinical consequences of COVID-19 in patients with diabetes.


Ключевые слова

цукровий діабет; гіперглікемія; хронічні ускладнення; COVID-19

diabetes mellitus; hyperglycemia; chronic complications; COVID-19

doi: http://dx.doi.org/10.22141/2224-0721.19.6.2023.1315

Для ознакомления с полным содержанием статьи необходимо оформить подписку на журнал.


Список литературы

  1. Zhu N., Zhang D., Wang W., Li X., Yang B. et al. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N. Engl. J. Med. 2020. 382. 727-33. doi: 10.1056/NEJMoa2001017.
  2. World Health Organization Director-General’s Opening Remarks at the Media Briefing on COVID-19-11 2020. Available from: https://www.who.int/director-general/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-covid-19---11-march-2020.
  3. Guy R.K., DiPaola R.S., Romanelli F., Dutch R.E. Rapid repurposing of drugs for COVID-19. Science. 2020. 368. 829-30. doi: 10.1126/science.abb9332.
  4. Lippi G., Sanchis-Gomar F., Henry B.M. COVID-19: unravelling the clinical progression of nature’s virtually perfect biological wea–pon. Ann. Transl. Med. 2020. 8. 693-693. doi: 10.21037/atm-20-3989.
  5. Onder G., Rezza G., Brusaferro S. Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy. JAMA. 2020. doi: 10.1001/jama.2020.4683.
  6. Saeedi P., Petersohn I., Salpea P., Malanda B., Karuranga S. et al. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045: results from the International Diabetes Federation Diabetes Atlas, 9th edition. Diabetes Res. Clin. Pract. 2019. 157. 107843. doi: 10.1016/j.diabres.2019.107843.
  7. Shah B.R., Hux J.E. Quantifying the Risk of Infectious Di–seases for People with Diabetes. Diabetes Care. 2003. 26. 510-3. doi: 10.2337/diacare.26.2.510.
  8. Muller L.M.A.J., Gorter K.J., Hak E., Goudzwaard W.L., Schellevis F.G. et al. Increased Risk of Common Infections in Patients with Type 1 and Type 2 Diabetes Mellitus. Clin. Infect. Dis. 2005. 41. 281-8. doi: 10.1086/431587.
  9. Yang J.K., Feng Y., Yuan M.Y., Yuan S.Y., Fu H.J. et al. Plasma glucose levels and diabetes are independent predictors for mortality and morbidity in patients with SARS. Diabet. Med. 2006. 3. 623-8. doi: 10.1111/j.1464-5491.2006.01861.x.
  10. Alqahtani F.Y., Aleanizy F.S., Ali El Hadi Mohamed R., Alanazi M.S., Mohamed N. et al. Prevalence of comorbidities in cases of Middle East respiratory syndrome coronavirus: a retrospective study. Epidemiol. Infect. 2019. 147. e35. doi: 10.1017/S0950268818002923.
  11. Rogers L.C., Lavery L.A., Joseph W.S., Armstrong D.G. All feet on deck — the role of podiatry during the COVID-19 pandemic: preventing hospitalizations in an overburdened healthcare system, reducing amputation and death in people with diabetes. J. Am. Podiatr. Med. Assoc. 2023. 113(2). 20-051. doi: 10.7547/20-051.
  12. Savchenko L.G., Digtiar N.I., Selikhova L.G., Kaidasheva E.I., Shlykova O.A. et al. Liraglutide exerts an anti-inflammatory action in obese patients with type 2 diabetes. Rom. J. Intern. Med. 2019. 57. 233-40. doi: 10.2478/rjim-2019-0003.
  13. Van Crevel R., van de Vijver S., Moore D.A.J. The global diabetes epidemic: what does it mean for infectious diseases in tropical countries? Lancet Diabetes Endocrinol. 2017. 5. 457-68. doi: 10.1016/S2213-8587(16)30081-X.
  14. Berbudi A., Rahmadika N., Tjahjadi A.I., Ruslami R. Type 2 Diabetes and its Impact on the Immune System. Curr. Diabetes Rev. 2020. 16. 442-9. doi: 10.2174/1573399815666191024085838.
  15. Reddy P., Lent-Schochet D., Ramakrishnan N., McLaughlin M., Jialal I. Metabolic syndrome is an inflammatory disorder: a conspiracy between adipose tissue and phagocytes. Clin. Chim. Acta. 2019. 496. 35-44. doi: 10.1016/j.cca.2019.06.019.
  16. Mehta P., McAuley D.F., Brown M., Sanchez E., Tattersall R.S., Manson J.J. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020. 395. 1033-4. doi: 10.1016/S0140-6736(20)30628-0.
  17. Guo W., Li M., Dong Y., Zhou H., Zhang Z. et al. Diabetes is a risk factor for the progression and prognosis of COVID-19. Diabetes Metab. Res. Rev. 2020. 36. doi: 10.1002/dmrr.3319.
  18. Park J.E., Pichiah P.B.T., Cha Y.-S. Vitamin D and Metabolic Diseases: Growing Roles of Vitamin D. J. Obes. Metab. Syndr. 2018. 27. 223-32. doi: 10.7570/jomes.2018.27.4.223.
  19. Singh A.K., Gupta R., Ghosh A., Misra A. Diabetes in COVID-19: prevalence, pathophysiology, prognosis and practical considerations. Diabetes Metab. Syndr. Clin. Res. Rev. 2020. 14. 303-10. doi: 10.1016/j.dsx.2020.04.004.
  20. Shenoy A., Ismaily M., Bajaj M. Diabetes and COVID-19: a global health challenge. BMJ Open Diabetes Res. Care. 2020. 8. e001450. doi: 10.1136/bmjdrc-2020-001450.
  21. Angelidi A.M., Belanger M.J., Mantzoros C.S. Commentary: COVID-19 and diabetes mellitus: what we know, how our patients should be treated now, and what should happen next. Metabolism. 2020. 107. 154245. doi: 10.1016/j.metabol.2020.154245.
  22. Gentile S., Strollo F., Ceriello A. COVID-19 infection in Ita–lian people with diabetes: lessons learned for our future (an experien–ce to be used). Diabetes Res. Clin. Pract. 2020. 162. 108137. doi: 10.1016/j.diabres.2020.108137.
  23. Wu Z., McGoogan J.M. Characteristics of and Important Lessons from the Coronavirus Disease 2019 (COVID-19) Outbreak in China. JAMA. 2020. 323. 1239. doi: 10.1001/jama.2020.2648.
  24. Petrilli C.M., Jones S.A., Yang J., Rajagopalan H., O’Donnell L. et al. Factors associated with hospital admission and critical illness among 5279 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020. m1966. doi: 10.1136/bmj.m1966.
  25. Chow N., Fleming-Dutra K., Gierke R., Hall A., Hughes M. et al. Preliminary Estimates of the Prevalence of Selected Underlying Health Conditions Among Patients with Coronavirus Disease 2019 — United States, February 12 — March 28, 2020. MMWR Morb. Mortal Wkly Rep. 2020. 69. 382-6. doi: 10.15585/mmwr.mm6913e2.
  26. Shi H., Han X., Jiang N., Cao Y., Alwalid O. et al. Radiolo–gical findings from 81 patients with COVID-19 pneumonia in Wuhan, China: a descriptive study. Lancet Infect. Dis. 2020. 20. 425-34. doi: 10.1016/S1473-3099(20)30086-4.
  27. Xu S., Fu L., Fei J., Xiang H.-X., Xiang Y. et al. Acute kidney injury at early stage as a negative prognostic indicator of patients with COVID-19: a hospital-based retrospective analysis. MedRxiv. 2020. 2020.03.24.20042408. doi: 10.1101/2020.03.24.20042408.
  28. Wang G., Wu C., Zhang Q., Wu F., Yu B. et al. Epidemiological and Clinical Features of Corona Virus Disease 2019 (COVID-19) in Changsha, China. SSRN Electron. J. 2020. doi: 10.2139/ssrn.3548770.
  29. Hu L., Chen S., Fu Y., Gao Z., Long H. et al. Risk Factors Associated with Clinical Outcomes in 323 Coronavirus Disease 2019 (COVID-19) Hospitalized Patients in Wuhan, China. Clin. Infect. Dis. 2020. 71. 2089-98. doi: 10.1093/cid/ciaa539.
  30. Eastin C., Eastin T. Clinical Characteristics of Coronavirus Disease 2019 in China. J. Emerg. Med. 2020. 58. 711-2. doi: 10.1016/j.jemermed.2020.04.004.
  31. Yang X., Yu Y., Xu J., Shu H., Xia J. et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study. Lancet Respir. Med. 2020. 8. 475-81. doi: 10.1016/S2213-2600(20)30079-5.
  32. Zhang J., Dong X., Cao Y., Yuan Y., Yang Y. et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020. 75. 1730-41. doi: 10.1111/all.14238.
  33. Zhou F., Yu T., Du R., Fan G., Liu Y. et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020. 395. 1054-62. doi: 10.1016/S0140-6736(20)30566-3.
  34. Wang X., Fang X., Cai Z., Wu X., Gao X. et al. Comorbid Chronic Diseases and Acute Organ Injuries Are Strongly Correlated with Disease Severity and Mortality among COVID-19 Patients: A Systemic Review and Meta-Analysis. Research. 2020. 2020. 1-17. doi: 10.34133/2020/2402961.
  35. Tian W., Jiang W., Yao J., Nicholson C.J., Li R.H. et al. Predictors of mortality in hospitalized COVID-19 patients: a systematic review and meta-analysis. J. Med. Virol. 2020. 92. 1875-83. doi: 10.1002/jmv.26050.
  36. Kumar A., Arora A., Sharma P., Anikhindi S.A., Bansal N. et al. Is diabetes mellitus associated with mortality and severity of COVID-19? A meta-analysis. Diabetes Metab. Syndr. Clin. Res. Rev. 2020. 14. 535-45. doi: 10.1016/j.dsx.2020.04.044.
  37. Huang I., Lim M.A., Pranata R. Diabetes mellitus is associated with increased mortality and severity of disease in COVID-19 pneumonia — a systematic review, meta-analysis, and meta-regression. Diabetes Metab. Syndr. Clin. Res. Rev. 2020. 14. 395-403. doi: 10.1016/j.dsx.2020.04.018.
  38. Chan-Yeung M., Xu R.-H. SARS: epidemiology. Respirology. 2003. 8. S9-14. doi: 10.1046/j.1440-1843.2003.00518.x.
  39. Wan S., Xiang Y., Fang W., Zheng Y., Li B. et al. Clinical features and treatment of COVID-19 patients in northeast Chongqing. J. Med. Virol. 2020. 92. 797-806. doi: 10.1002/jmv.25783.
  40. Wang L., He W., Yu X., Hu D., Bao M. et al. Coronavirus disease 2019 in elderly patients: characteristics and prognostic factors based on 4-week follow-up. J. Infect. 2020. 80. 639-45. doi: 10.1016/j.jinf.2020.03.019.
  41. Liu Y., Sun W., Li J., Chen L., Wang Y. et al. Clinical features and progression of acute respiratory distress syndrome in coronavirus disease 2019. MedRxiv. 2020. 2020.02.17.20024166. doi: 10.1101/2020.02.17.20024166.
  42. Wang D., Hu B., Hu C., Zhu F., Liu X. et al. Clinical Cha–racteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020. 323. 1061. doi: 10.1001/jama.2020.1585.
  43. Wu C., Chen X., Cai Y., Xia J., Zhou X. et al. Risk Factors Associated with Acute Respiratory Distress Syndrome and Death in Patients with Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern. Med. 2020. 180. 934. doi: 10.1001/jamainternmed.2020.0994.
  44. Moss M., Guidot D.M., Steinberg K.P., Duhon G.F., Treece P. et al. Diabetic patients have a decreased incidence of acute respiratory distress syndrome. Crit. Care Med. 2000. 28. 2187-92. doi: 10.1097/00003246-200007000-00001.
  45. Fu L., Wang B., Yuan T., Chen X., Ao Y. et al. Clinical cha–racteristics of coronavirus disease 2019 (COVID-19) in China: a systematic review and meta-analysis. J. Infect. 2020. 80. 656-65. doi: 10.1016/j.jinf.2020.03.041.
  46. Huang C., Wang Y., Li X., Ren L., Zhao J. et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020. 395. 497-506. doi: 10.1016/S0140-6736(20)30183-5.
  47. Brufsky A. Hyperglycemia, hydroxychloroquine, and the COVID-19 pandemic. J. Med. Virol. 2020. 92. 770-5. doi: 10.1002/jmv.25887.
  48. Classification and Diagnosis of Diabetes. Diabetes Care. 2017. 40. S11-24. doi: 10.2337/dc17-S005.
  49. Olariu E., Pooley N., Danel A., Miret M., Preiser J.-C. A systematic scoping review on the consequences of stress-related hyperglycaemia. PLoS One. 2018. 13. e0194952. doi: 10.1371/journal.pone.0194952.
  50. Umpierrez G.E., Isaacs S.D., Bazargan N., You X., Tha–ler L.M., Kitabchi A.E. Hyperglycemia: An Independent Marker of In-Hospital Mortality in Patients with Undiagnosed Diabetes. J. Clin. Endocrinol. Metab. 2002. 87. 978-82. doi: 10.1210/jcem.87.3.8341.
  51. Sardu C., D’Onofrio N., Balestrieri M.L., Barbieri M., Rizzo M.R. et al. Outcomes in Patients with Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control? Diabetes Care. 2020. 43. 1408-15. doi: 10.2337/dc20-0723.
  52. Summary of recommendations regarding COVID-19 in children with diabetes: keep calm and mind your diabetes care and public health advice. Pediatr. Diabetes. 2020. 21. 413-4. doi: 10.1111/pedi.13013.
  53. Bousquet J., Agache I., Blain H., Jutel M., Ventura M.T. et al. Management of anaphylaxis due to COVID-19 vaccines in the elderly. Allergy. 2021. 76. 2952-64. doi: 10.1111/all.14838.
  54. Mahrooz A., Muscogiuri G., Buzzetti R., Maddaloni E. The complex combination of COVID-19 and diabetes: pleiotropic changes in glucose metabolism. Endocrine. 2021. 72. 317-25. doi: 10.1007/s12020-021-02729-7.
  55. Ji H.-L., Zhao R., Matalon S., Matthay M.A. Elevated Plasmin(ogen) as a Common Risk Factor for COVID-19 Susceptibility. Physiol. Rev. 2020. 100. 1065-75. doi: 10.1152/physrev.00013.2020.
  56. Xu Z., Shi L., Wang Y., Zhang J., Huang L. et al. Pathologi–cal findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 2020. 8. 420-2. doi: 10.1016/S2213-2600(20)30076-X.
  57. Boiko D.I., Skrypnikov A.M., Shkodina A.D., Hasan M.M., Ashraf G.M., Rahman M.H. Circadian rhythm disorder and anxiety as mental health complications in post-COVID-19. Environ. Sci. Pollut. Res. 2022. 29. 28062-9. doi: 10.1007/s11356-021-18384-4.
  58. Purdenko T.I., Lytvynenko N.V., Ostrovskaya L.I., Hladka V.M., Sylenko H.Y., Tarianyk K.A. On the problem of syncopal conditions in the neurological practice. Wiad. Lek. 2018. 71(9). 1823-1828 (in Ukrainian).
  59. Poissy J., Goutay J., Caplan M., Parmentier E., Duburcq T. et al. Pulmonary Embolism in Patients with COVID-19. Circulation. 2020. 142. 184-6. doi: 10.1161/CIRCULATIONAHA.120.047430.
  60. Lima-Martínez M.M., Carrera Boada C., Madera-Silva M.D., Marín W., Contreras M. COVID-19 y diabetes mellitus: una relación bidireccional. Clínica e Investig. En Arterioscler. 2021. 33. 151-7. doi: 10.1016/j.arteri.2020.10.001.
  61. Pankiv V., Pashkovska N., Pankiv I., Maslyanko V., Tsaryk I. Pathophysiological and clinical aspects of interaction between coronavirus disease 2019 and thyroid. Mìžnarodnij endokrinologìčnij žurnal. 2021. 17(4). 329-333. doi: 10.22141/2224-0721.17.4.2021.237348.
  62. Boiko D.I., Shkodina A.D., Hasan M.M., Bardhan M., Kazmi S.K. et al. Melatonergic Receptors (Mt1/Mt2) as a Potential Additional Target of Novel Drugs for Depression. Neurochem. Res. 2022. 47. 2909-24. doi: 10.1007/s11064-022-03646-5.

Вернуться к номеру